These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17511934)

  • 1. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
    Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
    Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
    Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
    J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I; David M; Stemmer SM
    Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
    Seiverling EV; Fernanadez EM; Adams D
    J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 8. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib-induced scalp perifolliculitis.
    Rallis E; Petronic-Rosic V; Korfitis C
    Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
    Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
    Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of bullous dermatitis induced by erlotinib.
    Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
    Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purpuric drug eruption and alopecia induced by erlotinib.
    Nakamura-Wakatsuki T; Yamamoto T
    Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
    Cholongitas E; Pipili C; Ioannidou D
    J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.